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Using tissue microarrays (TMAs) we studied COX2/PPARG immunoreactivity in a broad spectrum of tumors focussing on
clinicopathological correlations and the outcome of patients with malignant melanoma (MM). TMA-1 contained normal and
tumor tissues (n = 3448) from 47 organs including skin neoplasms (n = 323); TMA-2 88 primary MM, 101 metastases, and
161 benign nevi. Based on a biomodulatory approach combining COX/PPAR-targeting with metronomic low-dose chemotherapy
metastases of 36 patients participating in a randomized trial with metastatic (stage IV) melanoma were investigated using TMA-3.
COX2/PPARGimmunoreactivitysigniﬁcantlyincreasedfromnevitoprimaryMMandmetastases;COX2positivitywasassociated
with advanced Clark levels and shorter recurrence-free survival. Patients with PPARG-positive metastases and biomodulatory
metronomic chemotherapy alone or combined with COX2/PPARG-targeting showed a signiﬁcantly prolonged progression-free
survival. Regarding primary MM, COX2 expression indicates an increased risk of tumor recurrence. In metastatic MM, PPARG
expression may be a predicitive marker for response to biomodulatory stroma-targeted therapy.
1.Introduction
Cyclooxygenases (COXs) catalyze the ﬁrst rate-limiting step
in the conversion of arachidonic acid to prostaglandins. Two
COXisoenzymeshavebeenidentiﬁed:COX1isconstitutively
expressed in most tissues and mediates the synthesis of
prostaglandins in normal physiological processes, whereas
COX2 is not detectable in most normal tissues but is
rapidly induced by various stimuli such as inﬂammatory
reactions [1]. COX2 is also expressed in various tumor
types [2], and levels of expression have been shown to
correlate with invasiveness and prognosis in some tumor
entities, suggesting an important role of COX2 in tumor
development and progression. Epidemiological studies show
that prolonged COX2 inhibition through acetylsalicylic acid
or other nonsteroidal anti-inﬂammatory drugs (NSAIDs)
might oﬀer some protection against colon cancer and some
other malignancies [3, 4]. Accordingly, in animal experi-
ments COX2 inhibitors can reduce the incidence of colon
carcinoma in APC knockout mice treated with chemical
carcinogens [5]. The mechanism by which COX2 expression
accelerates tumorigenesis is poorly understood. However, a
potential role of COX2 in epithelial and melanocytic skin
cancer development is also not unlikely, since COX2 is
frequently expressed in malignant melanomas (MMs) [6, 7]
and squamous cell carcinomas of the skin [8, 9].2 PPAR Research
The peroxisome proliferator-activated receptor (PPAR)
is a member of the nuclear hormone receptor subfamily
of ligand-activated transcription factors. There are three
known subtypes of peroxisome proliferator-activated recep-
tors; PPARA, PPARD, and PPARG. The latter is involved
in physiological adipocyte diﬀerentiation and diﬀerentially
e x p r e s s e di ns e v e r a lt y p e so fh u m a nc a n c e r s[ 10], for
example,inprostatecancer[11,12],breastadenocarcinomas
[13], overian cancer [14, 15], lung cancer [16], and colon
cancer[17].Accordingly,PPARligandswereshowntoinhibit
the growth of cells from diﬀerent cancer lineages in vitro
[18]. In human melanoma cell lines the antiproliferative
and apoptosis-inducing eﬀect of PPARG ligands was demon-
strated, too [19, 20].
Current research data and clinical experience sug-
gest that PPARA/G can mediate both direct antitumoral
and immunomodulatory eﬀe c t sa n dab r o a ds p e c t r u mo f
stroma modulating activity including antiangiogenic, anti-
inﬂammatory, and immunoaugmentative eﬀects [21, 22].
Examples of superadditive complementation of PPARG
agonists by COX2 inhibitors and metronomic chemotherapy
are well-documented experimentally and in clinical trials,
respectively [10, 16, 23].
We had studied such combined tumor-stroma-targeted
cancer therapy using PPARG agonists and COX2 inhibit-
ors in the second-line treatment of advanced metastatic
melanoma disease [22, 23]. In a randomized multi-
institutional phase II trial including 76 mostly chemorefrac-
torypatientswithprogressionofmetastaticmelanoma(stage
IV melanoma according to AJCC criteria), we had observed
a signiﬁcantly prolonged progression-free survival in the
groupofpatientsthatreceivedangiostaticallyscheduledlow-
dose metronomic chemotherapy (trofosfamide) in combi-
nation with a PPARG agonist (pioglitazone) and a COX2
inhibitor (rofecoxib) compared to the group of patients who
received metronomic chemotherapy alone [22]. Accordingly,
tumor-associated inﬂammatory and angiogenic processes
mediated by COX2 overexpression or PPARG deﬁciency
were suggested to play a pivotal role in the biology of
melanoma progression [22]. However, there is insuﬃcient
data on the expression of both target molecules; therefore,
their prognostic and therapeutic relevance in MM is still
unclear.
The study presented herein is based on a high-
throughput tissue microarray (TMA) analysis, a highly eﬃ-
cient technology for investigating large numbers of tumors.
To the best of our knowledge this is the largest study of this
topic which can link expression data with extensive follow-
up data of melanoma patients, respectively. In addition,
as we gather extensive data on various other cancers and
normal tissues (47 organs and tissue entities) we can put the
speciﬁties of the melanoma data into a broader oncologic
context.
2.MaterialsandMethods
2.1. Tissue Microarrays (TMAs). TMA construction was per-
formed as described previously [24]. The local Institutional
Review Boards of the Universities of Regensburg and Basel
granted approval for this project.
The ﬁrst TMA (TMA-1) contained formalin-ﬁxed,
paraﬃn-embedded tissue punches from the archives of the
Institute of Pathology, University of Basel, Switzerland. A
comprehensive TMA was created by transferring representa-
tive tissue cylinders with a diameter of 0.6mm to seven new
paraﬃn blocks as described by Bubendorf et al. [25]. Rep-
resentative areas of diﬀerent subtypes for the most frequent
tumor entities and their corresponding nontumorous tissue
were selected for analysis. Four μm sections of the resulting
TMA block were cut and mounted to an adhesive-coated
slide system (Instrumedics Inc. Hackensack, NJ, USA). The
constructed multitumor TMA-1 consisted of 3448 primary
tumors from 132 diﬀerent tumor subtypes and 26 diﬀerent
normal tissues and allowed us to determine the prevalence
of COX2 and PPARG expression in nontumorous tissues
and corresponding malignant tumors. Samples from skin
(n = 330), lung (n = 217), brain (n = 228), breast
(n = 218), colon (n = 204), soft tissue (n = 150), salivary
gland (n = 152), testis (n = 126), ovary (n = 140), and
kidney (n = 144) were the major tissues assembled on
this TMA. The evaluation of tissue and clinical data was
performedonthebasisofanonymizedpatientdataaccording
to the regulations of the University of Basel Institutional
Review Board. Detailed tumor and tissue characteristics can
be found in supplementary Tables 1 and 2 in Supplementary
Material available online at doi:10.1155/2010/848645. The
skin-related data sets were extracted and are summarized in
Table 1.
The second TMA (TMA-2) was constructed as described
by Wild et al. [26] and contained a total of 350 formalin-
ﬁxed, paraﬃn-embedded human tissues: 88 (25.1%) pri-
mary malignant melanomas, 101 (28.9%) metastases, and
161 (46.0%) benign nevi. H&E-stained slides of all tumors
were evaluated by two surgical pathologists (T.V., P.J.W.).
Clinical follow-up data, provided by the Central Tumor
Registry of the University of Regensburg, were available
for all patients with primary malignant melanomas (n =
88). The median follow-up for all patients was 54 months
(range 0 to 135 months), whereas the median follow-up for
censored patients (n = 74) was 63.5 months. Characteristic
parameters of TMA-2 are summarized in Table 2.
The third TMA (TMA-3) was constructed on the basis
of a randomized multi-institutional phase II trial using an
angiostatic biomodiulatory approach to assess the impact
of COX2- and PPAR-targeted therapy in combination
with metronomic low-dose chemotherapy in patients with
advanced metastatic stage IV melanoma [22]. The clinical
trial was designed to select metronomic chemotherapy alone
(arm A: trofosfamide 50mg orally three times daily, day 1+)
or combined anti-inﬂammatory/angiostatic treatment (arm
B: trofosfamide as mentioned above plus rofecoxib 25mg
orally, day 1+, and pioglitazone 60mg orally, day 1+) for fur-
ther evaluation. A total of 76 patients, mostly (>60%) refrac-
tory to at least one previous chemotherapy with maximum
tolerated doses, and progression of metastatic melanoma
were included; from the Institute of Pathology and the
Department of Dermatology (University of Regensburg,PPAR Research 3
Table 1: COX2 and PPARG expression analysis of skin tumors using TMA-1.
Tumor entity Cytoplasmic COX2 immunoreactivity Nuclear PPARG immunoreactivity P†
n analyzable 0 (n)1 + ( n)2 + ( n)3 + ( n) P∗ n analyzable 0 (n)1 + ( n)2 + ( n)3 + ( n) P∗
TMA-1: total (n = 323) 186 34 86 54 12 212 143 50 19 0 .0003
Melanocytic lesions
Malignant melanoma 38 0 16 17 5 .02 41 21 8 12 0 .001 .01
Benign nevus 19 4 7 8 0 24 22 2 0 0 1.00
Epithelial tumors
Squamous cell carcinoma 30 3 10 11 6 .07 33 23 7 3 0 .001 .62
Basal cell carcinoma 31 7 16 7 1 33 11 21 1 0 .57
Connective tissue tumors
Kaposi sarcoma 15 6 8 1 0
.61
18 13 5 0 0
.13
1.00
Benign histiocytoma 16 8 7 1 0 22 19 1 2 0 .47
Capillary hemangioma 14 3 9 2 0 18 16 2 0 0 1.00
Appendix tumors
Benign sebaceous adenoma 23 3 13 7 0 23 18 4 1 0 1.00
∗Fisher’s exact test (2-sided); bold face representing signiﬁcant data.
†Fisher’s exact test (2-sided); association of COX2 and PPARG IHC within single tumor entities.
Table 2: Clinicopathologic parameters in relation to COX2 immunohistochemistry using TMA-2.
Variable Categorization Cytoplasmic COX2 immunoreactivity Nuclear PPARG immunoreactivity P†
n analyzable 0 (n)1 + ( n)2 + ( n)3 + ( n) P† n analyzable 0 (n)1 + ( n)2 + ( n)3 + ( n )
Primary malignant melanomas
Clark level
I I 4 3 100
.004
22 0 0 0
.793 I I I 1 4 3 632 1 2 1 1 100
IV 52 2 27 15 8 52 39 10 2 1
V 1 3 4 261 1 1 9 101
Tumor thickness
≤2.0mm 35 8 17 6 4 .104 31 24 6 1 0 .762
>2.0mm 49 4 20 18 7 47 37 7 1 2
Growth pattern∗
SSM 37 6 15 11 5
.748
85 3 0 0
.685
L M M 3 2 010 3 6 2 9 610
NM 29 2 14 9 4 5 4 1 0 0
A L M 6 1 311 2 7 2 1 312
O N A 9 1 521 2 2 000
TP53 immunoreactivity
<5% 67 11 28 20 8 .308 63 49 10 2 2 .883
≥5% 15 0 8 4 3 15 12 3 0 0
Ki-67 labeling index
<5% 68 11 29 18 10 .295 64 53 9 1 1 .101
≥5% 14 0 7 6 1 14 8 4 1 1
Melanoma metastases
Lymph node 42 3 9 4 26 .013 42 32 6 2 2 .136
S k i n 5 6 6 2 761 7 5 3 3 2 1 81 2
Benign nevi
Compound & junctional 47 39 7 1 0
<.001
53 53 0 0 0
— Dermal 21 15 6 0 0 45 45 0 0 0
Congenital 51 4 45 2 0 50 50 0 0 0
∗SSM, superﬁcal spreading melanoma; LMM, lentigo maligna melanoma; NM, nodular melanoma; ALM, akro-lentiginous melanoma; NOS, not otherwise
speciﬁed.
†Fisher’s exact test (two-sided), bold face representing signiﬁcant data.4 PPAR Research
Germany) 194 formalin-ﬁxed paraﬃn-embedded metastatic
tissues of 36 patients (47%) were available for further
immunohistochemical analysis. The local ethic committee
had approved the study.
Prior to TMA-construction, H&E-stained slides of all
specimens were evaluated by two dermatopathologists (T.V.,
S.M.) to identify representative metastatic areas. Clinical
follow-up data with a median follow-up period of 9 months
(range 1–43 months) were available for 35 melanoma
patients (97%), that is, 12 patients (33%) who received
metronomic chemotherapy alone (arm A) and 23 patients
(64%) with combined anti-inﬂammatory/angiostatic treat-
ment (arm B). Median follow-up of censored patients was 7
months (range 2–43 months). Characteristic parameters of
TMA-3 are given in Table 4.
2.2. Immunohistochemistry (IHC). Immunohistochemical
studies utilized an avidin-biotin peroxidase method with a
3-amino-9-ethylcarbazole (AEC) chromatogen. After anti-
gen retrieval (steam boiler with citrate-buﬀer, pH 6.0 for
20minutes) immunohistochemistry was carried out apply-
ing the ZytoChemPlus HRP Broad Spectrum Kit (Zytomed
Systems, Berlin, Germany) according to the manufacturer’s
instructions. The following primary antibodies were used:
anti-COX2 (mouse monoclonal, Cayman Chemical, Ann
Arbor, Mich, USA; dilution 1 : 200, ﬁnal concentration
2.5μg/mL),anti-PPARG(rabbitmonoclonal,CellSignalling,
New England Biolabs GmbH, Frankfurt am Main, Germany;
dilution 1 : 400), anti-TP53 (mouse monoclonal IgG, clone
Bp53-12 (sc-263), Santa Cruz Biotechnology Santa Cruz,
Calif, USA; dilution 1 : 1000), and anti-Ki-67 (rabbit mon-
oclonal, clone MIB1; DakoCytomation GmbH, Hamburg,
Germany; dilution 1 : 10, ﬁnal concentration 5μg/mL).
As a positive control for COX2 and PPARG IHC, a colon
carcinoma with known COX2 and PPARG expression was
chosen. Normal tissue samples of 10 diﬀerent organs were
considered as negative controls. Two pathologists performed
a blinded evaluation of the stained slides. Cytoplasmic COX2
and nuclear PPARG immunoreactivity were estimated using
an arbitrary semiquantitative four-step scoring system (0-
3+), based on the intensity of cytoplasmic COX2 staining
[6] and the percentage of PPARG positive cell nuclei [7]: 0
(negative): no cytoplasmic COX2 staining/PPARG staining
0% of cell nuclei; 1+: weak COX2 staining/PPARG staining
1 to 9%; 2+: moderate COX2 staining/PPARG staining 10
to 50%; 3+: strong COX2 staining/ PPARG staining greater
than 50%. Causes of noninterpretable results included lack
of tumor tissue and presence of necrosis or crush artifact.
T h ep e r c e n t a g eo ft u m o rc e l l sw i t hn u c l e a rK i - 6 7a n dT P 5 3
staining was determined as described previously [27]. Ki-
67/TP53 labeling was considered high if at least 5% of the
tumor cells were positive.
2.3. Statistical Analysis. Specimens on TMA-1 and TMA-2
were considered independently. Concerning TMA-3, COX2
and PPARG immunoreactivity were examined for a mean of
5 metastatic samples per patient (range 1–15); the median
level of COX2 and PPARG immunoreactivity was chosen
for further analyses using the SPSS version 16.0 (SPSS,
Chicago,Ill,USA).P-values<.05wereconsideredsigniﬁcant.
Contingency table analysis and two-sided Fisher’s exact
tests or X2-tests were used to study statistical associations
betweenclinicopathologicalandimmunohistochemicaldata.
Retrospective overall and progression-free survival curves
comparing patients with and without any of the variables
were calculated using the Kaplan-Meier method, with sig-
niﬁcance evaluated by two-sided log rank statistics. For the
analysis of progression-free survival, patients were censored
at the time of their last progression-free clinical follow-up
appointment. For the analysis of overall survival, patients
were censored at the time of their last clinical follow-up
appointment or at their date of death not related to the
tumor. For multiple testing, the closed test principle was
used.
3. Results
3.1. TMA-1. Investigation of COX2 and PPARG protein
expression in 323 benign and malignant skin tumors using
a comprehensive multitumor TMA (TMA-1) was infor-
mative in 57.6% (186/323) and 65.6% (212/323) of cases.
COX2 and PPARG expression of any intensity (score 1+-
3+) was detected in 81.7% (152/186) and 32.5% (69/212)
of informative cases, respectively. Table 1 summarizes the
expression data and statistical analysis of COX2 and PPARG
immunoreactivity of each skin tumor entity on TMA-1.
For connective tissue tumors (Kaposi sarcoma, capillary
hemangioma, benign histiocytoma) no signiﬁcant diﬀer-
ences could be found in benign versus malignant tumors
(P = .61 and P = .13). Regarding epithelial tumors
(squamous cell carcinomas, basal cell carcinomas) positive
PPARG staining was detected signiﬁcantly more often in
b a s a lc e l lc a r c i n o m a st h a ni ns q u a m o u sc e l lc a r c i n o m a s
(P = .001). Surprisingly, 86.9% of benign skin adnexal
tumors (sebaceous adenomas) were positive for COX2;
21.7% positive for PPARG. Regarding melanocytic lesions,
100% (38/38) of primary melanomas and 78.9% (15/19) of
benign nevi revealed at least weak COX2 immunoreactivity
(score 1+-3+); 48.7% (20/41) of primary melanomas and
8.3% (2/24) of benign nevi demonstrated PPARG positivity
(1+-2+). Accordingly, compared to benign nevi, expression
of both COX2 and PPARG was signiﬁcantly increased in
primary melanomas (P = .02 and P = .001).
Besides skin tumors, COX2 and PPARG expression was
analyzed in many other benign and malignant tissue types
from 46 diﬀerent organs using a comprehensive multitumor
TMA-1. As shown in supplementary Tables 1 and 2, diﬀer-
ential COX2 and PPARG expression between normal and
neoplastic tissue could be observed for almost every tissue
type investigated. In prostate cancer, for example, COX2
expression continuously increased from prostatic hyperpla-
sia to prostatic intraepithelial neoplasia (PIN) to organ-
conﬁned prostate cancer to hormone-refractory prostate
cancer to metastatic disease (supplementary Figures 1A).
3.2. TMA-2. Based on the results of TMA-1, a second TMA
(TMA-2) with clinical follow-up data sampling primaryPPAR Research 5
COX2, score 0
(a)
COX2, score 3+
(b)
PPARG, score 0
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(d)
Figure 1: Immunohistochemical COX2 and PPARG staining of malignant melanomas on TMA-2. Original magniﬁcation 10x (insets 200x).
Representative examples of a primary malignant melanoma with negative (a) and strong (b) immunoreactivity for COX2. Representative
examples of a primary malignant melanoma with negative (c) and strong (d) immunoreactivity for PPARG.
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Figure 2: Cumulative bar charts of COX2 (a) and PPARG (b) immunoreactivity in melanocytic skin tumors using TMA-2.6 PPAR Research
malignant melanomas and melanoma metastases as well as
benign nevi was constructed. COX2 and PPARG immunore-
activity was informative in 86.0% (301/350) and 91.7%
(321/350) of cases, respectively. Expression of COX2 and
PPARG of any intensity was detected in 73.8% (222/301)
and in 15.0% (48/321) of informative cases. Representative
negative and positive COX2 and PPARG immunostaining
patterns in malignant melanoma are shown in Figures
1(a)–1(d). Figures 2(a) and 2(b) summarize the results of
COX2 and PPARG IHC for primary melanomas, metastases,
and nevi on TMA-2. The percentage of COX2 positive
cases signiﬁcantly increased from benign nevi (51%) to
primary melanomas (86%) and melanoma metastases (91%;
P<. 001; Figure 2(a)). Likewise, PPARG immunoreactivity
signiﬁcantly increased from benign nevi (0%) to malignant
melanomas (22%) and melanoma metastases (33%; P<
.001; Figure 2(b)). Clinicopathologic variables of melanoma
patients were correlated with COX2 and PPARG expression
(Table 2).Inprimarymelanomas,positiveCOX2immunore-
activity was signiﬁcantly related to advanced Clark levels
(P = .004), but no other clinicopathologic variables such
as tumor growth pattern, p53 immunoreactivity, and Ki-
67 labeling index. Skin metastases demonstrated a gradually
weaker COX2 immunoreactivity compared with lymph node
metastases (P = .013). Among the various types of benign
nevionTMA-2,COX2expressionwassigniﬁcantlyincreased
in congential nevi compared to compound, junctional, and
dermal melanocytic nevi (P<. 001).
According to a univariate analysis, tumor progression
was signiﬁcantly related to both melanoma thickness and
COX2 immunoreactivity, respectively (P = .03; Table 3);
that is, expression of COX2 was associated with shorter
progression-free survival (P = .03; Figure 3). In contrast,
PPARGexpressionofprimarymelanomaswasnotassociated
with any of the variables neither the clinicopathologic ones
nor progression-free and overall survival (Tables 2 and 3).
3.3. TMA-3. Using TMA-3, the prognostic and therapeutic
meaning of COX2 and PPARG expression was analyzed
in patients with advanced metastatic melanoma disease
(n = 36). All patients received angiostatic biomodulatory
treatment with trofosfamide alone (arm A, n = 12) or in
combination with rofecoxib and pioglitazone (arm B, n =
24). COX2 and PPARG protein expression of metastatic tis-
sues was informative in all 36 cases. Expression of COX2 and
PPARG of any intensity was detected in 97.2% (35/36) and
in 38.9% (14/36) of patients, respectively. Clinicopathologic
variables of this cohort of patients with advanced metastatic
melanoma disease were compared relative to COX2 and
PPARG expression (Table 4).
Considering all 36 patients receiving biomodulatory
therapyexpressionofPPARG(score1+-3+)inthemetastases
was signiﬁcantly associated with longer progression-free
survival (P = .044) but not with overall survival (P =
.179; Figures 4(a) and 4(b)). Expression of COX2 (score
2+-3+) in the metastases, however, was not associated with
overall and progression-free survival, respectively (Figures
4(c) and 4(d)). Besides PPARG immunoreactivity, stage of
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Figure 3: Distribution of time (months) to tumor-related death
among patients with primary malignant melanomas showing
negative (0) or positive (1+ to 3+) COX2 immunoreactivity as
estimated by the Kaplan Meier method.
the primary melanoma was also a signiﬁcant prognostic
factor for progression-free survival (P = .016; Table 4).
In a multivariate Cox regression model, using primary
tumor stage (pTis-pT3 versus pT4) and PPARG expression
(negative versus positive) as covariates, neither PPARG
immunoreactivity nor primary tumor stage remained signif-
icant (data not shown).
4. Discussion
In this study, we demonstrate by a comprehensive mul-
titumor TMA that COX2 and PPARG are diﬀerentially
expressed in a broad spectrum of normal and malignant
tissues. Focussing on tumors of the skin we can further
conﬁrm that COX2 immunoreactivity of primary MM is
signiﬁcantlyassociatedwithadvancedClarklevels(P = .004)
and shorter recurrence-free survival (P = .03). PPARG
expression of primary MM, however, does not provide
signiﬁcant prognostic information. Yet, by analysis of COX2
and PPARG expression in MM metastases of patients who
had received biomodulatory therapy, we can show that only
the expression of PPARG is signiﬁcantly associated with
longer progression-free survival (P = .044). These ﬁndings
suggest that COX2 may mainly contribute to early steps
in melanoma progression, that is, growth and invasion of
primary MM, and becomes less essential in the advanced
metastatic setting of melanoma disease. Our study conﬁrms
the prognostic meaning of COX2 in patients with primaryPPAR Research 7
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Figure 4:Distributionoftime(months)todeathandtumorprogressionamongpatientswithadvancedmetastaticmelanomasincorrelation
with immunoreactivity of PPARG (a), (b) or COX2 (c), (d). All patients received biomodulatory treatment. The calculation was performed
according to the method of Kaplan and Meier.
MM and adds a new late-stage histolpathological marker,
PPARG, which may be predictive for responsiveness to
biomodulatory therapy in advanced metastatic MM. To our
knowledge this is the ﬁrst TMA study demonstrating that
PPARG protein expression may be a positive prognostic
marker indicating responsiveness to stroma-targeted therapy
in the late metastatic stage (IV) of MM disease, that is, in
patients refractory to conventional ﬁrst-line chemotherapy,
mostly with dacarbacine.
Consistent with previously published data on melan-
ocytic skin lesions [6, 7] our immunohistochemical analysis
of benign nevi, primary MM and MM metastases show that
COX2 and PPARG immunoreactivity signiﬁcantly increases
from benign nevi to primary MM and MM metastases. In
otherorgans,however,forexample,inprimarycancersofthe
lung versus normal lung tissues, decreased expression levels
of PPARG were found and associated with poor prognosis
[16]. At ﬁrst sight, these ﬁndings are in contrast to the
upregulation of PPARG in primary MM and MM metastases
versus benign nevi observed with TMA-2. But, as our data
also show, this upregulation does not correlate with the out-
come of MM patients indicating a distinct role of PPARG in
primary MM and MM metastases. Notably, in the advanced
metastatic stages of MM enclosed in this study, patients
with PPARG-positive metastases versus PPARG-negative
metastases show a signiﬁcant survival beneﬁt concerning
progression-free survival (P = .044) not dependent on
whether angiostatically scheduled metronomic chemother-
apy (trofosfamide) was administered alone or in combi-
nation with pioglitazone (PPARG agonist) and rofecoxib
(COX2inhibitor)asadditionalbiomodulatorytherapy.Con-
sideringPPARGorCOX2ascandidatesubstratesfortargeted
cancer therapy, it could be assumed that only patients with
PPARG- or COX2-positive metastases and additional8 PPAR Research
Table 3: Univariate analysis of factors regarding tumor progression and death.
Variable Categorization Tumor progression Death
na events Pb na events Pb
Age at diagnosis
≤60 years 48 25 0.7 48 7 0.6
>60 years 40 18 40 7
Gender
female 39 15 0.06 39 5 0.4
male 49 28 49 9
Clark level
(c)
II 5 0
0.4
50
0.3 III 15 8 15 2
IV 54 28 54 8
V1 3 7 1 3 4
Tumor thickness
≤2.0 mm 38 14 0.03 38 4 0.2
>2 . 0 m m5 02 9 5 01 0
Ki67 labeling index
<5% 33 17 0.7 33 7 0.9
≥5% 36 16 36 7
Cytoplasmic COX2 IHC
score 0 12 2 0.03 12 0 0.1
score 1+-3+ 72 39 72 14
Nuclear PPARG IHC
score 0 61 28 0.2 61 11 0.6
score 1+-3+ 17 10 17 2
aOnly initial and unifocal malignant melanomas were included;
bLog rank test (two-sided), bold face representing signiﬁcant data;
cAccording to UICC: TNM Classiﬁcation of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds.) Wiley, New York.
PPARG-agonistic or COX2-inhibitory therapy would show a
survival beneﬁt compared with patients treated with metro-
nomic chemotherapy alone. Yet, subgroup analysis with
TMA-3 did not show a signiﬁcant survival beneﬁt for these
patients. Thus, our study supports current concepts that
targeting COX2 and PPAR is more a tumor-stroma eﬀective
approach than an approach depending on the status of target
expression of the tumor itself [21, 22]. Possible explanations
of this paradoxon are multifaceted and complex. There may
be numerous “oﬀ-target” eﬀects of the involved drugs, for
example, modulation of COX2/PPARG-independent path-
ways [16, 18, 21]. According to the paradigm of biomod-
ulatory stroma targeting approaches [21, 28] the eﬀects
may be indirect due to modifying the tumor stroma; that
is, the therapy mainly exploits the dependence of cancer
tissues on functions of the stroma providing a permissive
and supportive environment for tumor cell survival, growth,
invasion, and formation of metastases. A variety of soluble
agents such as chemokines, growth factors, lipids, angio-
genetic factors, proteinases, and proteinase inhibitors are
involved in a complex crosstalk between tumor and stroma.
Stroma targeted approaches aim to inhibit tumor growth
and invasion by disruption of this tumor-stroma interaction.
Interestingly, stromal cells in the tumoral microenvironment
can also diﬀer from their normal counterparts in the expres-
sionofbiologicallymeaningfulmolecules[29]includingalso
COX2 and PPARG expression. For instance, upregulation of
these eﬀectors could be detected in stromal myoﬁbroblasts
surrounding colon adenocarcinomas [30].
Therefore, to fully evaluate and understand the potential
of COX2 and PPAR modulation in MM further studies
using TMAs punching the surrounding stroma may be
interesting future work. Based on the large comprehensive
amount of data gained in this study it seems to be
promising to further develop experimental protocols that
employ COX2/PPAR biomodulation. The combination of
both drugs is a logical consequence of experimental studies
indicating that COX2 and PPARG signalling pathways are
multiplyintertwined:PPARGligandssuppressCOX2expres-
sion induced by lipopolysaccharide and phorbol myristate
acetate in macrophages, astrocytes, and epithelial cells [16].
Moreover, expression of COX2 was suggested to be regulated
byanegativefeedbackloopinvolvingPPARGandNF-κB[31,
32]. PPARG agonists were shown to downregulate COX2,
potentiate the apoptotic eﬀects of chemotherapeutic agents,
and inhibit the growth of human melanoma cell lines in
vitro [19, 20]. Consistently, the randomized phase II trial by
Reichle et al. [22] including chemorefractory patients withPPAR Research 9
Table 4: Univariate analysis of factors regarding tumor progression and death using TMA-3.
Variable Categorization Death Tumor progression
n events P∗ n events P∗
Advance melanoma patients
Age
<60 years 12 7 0.152 12 11 0.163
≥6 0 y e a r s 2 21 4 2 21 8
Initial tumor stage
pT1 2 1 0.690 2 2 0.016
pT2 1 1 1 1
pT3 13 9 13 11
pT4 9 6 9 6
Melanoma in situ 1 0 1 1
Initial regional lymph node status
pN0 11 6 0.980 11 9 0.894
pN1 9 8 9 8
pN2 6 4 6 5
pN3 2 1 2 1
Study therapy
A: trofosfamide 12 10 0.570 12 10 0.898
B: trofosfamide + rofecoxib + pioglitazone 23 12 23 20
CRP
normal or < 30% decrease or increase 14 9 0.115 14 11 0.128
> 3 0 % d e c r e a s e 1 01 0 1 01 0
Cytoplasmic COX2 IHC
score 0 to 1+ 14 10 0.505 14 13 0.338
s c o r e 2 + t o 3 + 2 11 2 2 11 7
Nuclear PPARG IHC
score 0 22 15 0.179 22 21 0.044
score 1+ to 3+ 13 7 13 9
∗Log-rank test (two-sided).
progressive metastatic stage IV melanoma disease demon-
strated a signiﬁcantly prolonged progression-free survival
if metronomic low-dose chemotherapy (trofosfamide) was
combined with pioglitazone (PPARA and G agonist) and
rofecoxib (COX2 inhibitor). In summary, COX inhibitors
and PPAR agonists are a beneﬁcial adjunct in biomodulatory
therapy of MM rather independent of the presence of
the targeted substrates in the cancer cells themselves. The
expression of PPARG in the cancer, however, can indicate a
higher probability to respond to stroma-targeted approaches
also without drugs aiming on PPAR.
In conclusion, our study provides a late-stage prog-
nostic marker, PPARG expression, which correlates with
responsiveness to biomodulatory stroma-targeted therapy.
But it should be kept in mind that the indication for such
approaches cannot be solely based on selected features of the
cancer cell itself but must consider the complexitiy of the
stroma-tumor interaction, that is, the microenvironment,
including angiogenesis, immunoeﬀects, and functions of
the connective tissue as well. Therefore, further prospective
clinical trials are needed to validate the meaning of PPARG
and COX2 targeting as a part of biomodulatory therapeutic
approaches.
Abbreviations
MM: Malignant melanoma
TMA: Tissue microarray
IHC: Immunohistochemistry
COX2: Cyclooxygenase 2
PPARG: Peroxisome proliferator-activated
receptor gamma.
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